These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
328 related items for PubMed ID: 15614461
21. Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan. Izumikawa K, Watanabe A, Miyashita N, Ishida T, Hosono H, Kushimoto S, Kohno S. J Infect Chemother; 2014 Sep; 20(9):541-8. PubMed ID: 24934886 [Abstract] [Full Text] [Related]
27. A retrospective study of health care-associated pneumonia patients at Aichi Medical University hospital. Yamagishi Y, Mikamo H. J Infect Chemother; 2011 Dec; 17(6):756-63. PubMed ID: 21597900 [Abstract] [Full Text] [Related]
29. Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia in Japan. Yamamoto Y, Watanabe A, Goto H, Matsushima T, Abe S, Aoki N, Shimokata K, Mikasa K, Niki Y, Kohno S. J Infect Chemother; 2012 Aug; 18(4):544-51. PubMed ID: 22618270 [Abstract] [Full Text] [Related]
30. The hospitalist perspective on treatment of community-acquired bacterial pneumonia. Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. Postgrad Med; 2014 Mar; 126(2):18-29. PubMed ID: 24685965 [Abstract] [Full Text] [Related]
31. The emerging role of atypical pathogens in community-acquired pneumonia. Gleason PP. Pharmacotherapy; 2002 Jan; 22(1 Pt 2):2S-11S; discussion 30S-32S. PubMed ID: 11791627 [Abstract] [Full Text] [Related]
33. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia]. Sáez-Llorens X, Castaño E, Wubbel L, Castrejón MM, de Morales I, Vallarino D, de Atencio I, Muñiz L, Olsen K, McCracken GH. Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557 [Abstract] [Full Text] [Related]
34. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua. Matute AJ, Brouwer WP, Hak E, Delgado E, Alonso E, Hoepelman IM. Int J Antimicrob Agents; 2006 Nov; 28(5):423-7. PubMed ID: 17046211 [Abstract] [Full Text] [Related]
36. Empiric treatment of ambulatory community-acquired pneumonia: always include treatment for atypical agents. Marrie TJ. Infect Dis Clin North Am; 2004 Dec; 18(4):829-41. PubMed ID: 15555827 [Abstract] [Full Text] [Related]
37. [Coinfection with chlamydia and mycoplasma. Incidence in our environment]. Megías Montijano A, Gómez Campderá JA, Navarro Gómez ML, Urán Moreno M, González Sánchez MI, Rodríguez Fernández R. An Esp Pediatr; 2002 Aug; 57(2):110-5. PubMed ID: 12139864 [Abstract] [Full Text] [Related]
38. Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in pneumonia patients in four major hospitals in Trinidad. Nagalingam NA, Adesiyun AA, Swanston WH, Bartholomew M. New Microbiol; 2004 Oct; 27(4):345-51. PubMed ID: 15646048 [Abstract] [Full Text] [Related]
39. Demographics and microbiological profile of pneumonia in United Arab Emirates. Al-Muhairi S, Zoubeidi T, Ellis M, Nicholls MG, Safa W, Joseph J. Monaldi Arch Chest Dis; 2006 Mar; 65(1):13-8. PubMed ID: 16700188 [Abstract] [Full Text] [Related]
40. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Pelton SI, Hammerschlag MR. Clin Pediatr (Phila); 2005 Mar; 44(1):1-17. PubMed ID: 15678226 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]